However , in non-high-risk patients , the restricted mean survival time did not differ significantly between the two treatment groups ( 497 months [ 95 % CI 483-511 ] ) in the standard chemotherapy group vs 484 months [ 470-499 ] in the bevacizumab group ; p = 020 ) .